Cornelia Liedtke

12.9k total citations · 4 hit papers
95 papers, 7.6k citations indexed

About

Cornelia Liedtke is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Cornelia Liedtke has authored 95 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Cancer Research, 67 papers in Oncology and 35 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Cornelia Liedtke's work include Breast Cancer Treatment Studies (66 papers), Advanced Breast Cancer Therapies (32 papers) and HER2/EGFR in Cancer Research (31 papers). Cornelia Liedtke is often cited by papers focused on Breast Cancer Treatment Studies (66 papers), Advanced Breast Cancer Therapies (32 papers) and HER2/EGFR in Cancer Research (31 papers). Cornelia Liedtke collaborates with scholars based in Germany, United States and Switzerland. Cornelia Liedtke's co-authors include Gabriel N. Hortobágyi, Lajos Pusztai, Ana M. González-Angulo, Gϋnter von Minckwitz, W. Fraser Symmans, Attila Tordai, Fabrice André, Massimo Cristofanilli, Carsten Denkert and Andrew Tutt and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Cornelia Liedtke

91 papers receiving 7.5k citations

Hit Papers

Response to Neoadjuvant Therapy and Long-Term Survival in... 2008 2026 2014 2020 2008 2013 2009 2016 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
    2008 2.2k citations Cornelia Liedtke, Chafika Mazouni et al. Journal of Clinical Oncology profile →
  2. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study
    2013 928 citations Thorsten Kuehn, Ingo Bauerfeind et al. The Lancet Oncology profile →
  3. Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer
    2009 684 citations Cornelia Liedtke, Gabriel N. Hortobágyi et al. Journal of Clinical Oncology profile →
  4. Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
    2016 659 citations Cornelia Liedtke, Gϋnter von Minckwitz et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cornelia Liedtke Germany 29 4.4k 4.3k 2.6k 1.7k 1.3k 95 7.6k
Mark Basik Canada 41 2.9k 0.7× 2.8k 0.7× 3.5k 1.4× 1.3k 0.8× 1.0k 0.8× 142 7.2k
Rodrigo Dienstmann Spain 37 2.2k 0.5× 3.4k 0.8× 3.2k 1.3× 1.4k 0.8× 1.7k 1.3× 179 7.0k
Andrew H.S. Lee United Kingdom 37 3.5k 0.8× 4.0k 0.9× 1.4k 0.5× 2.3k 1.4× 1.1k 0.9× 88 7.1k
Pär‐Ola Bendahl Sweden 44 3.0k 0.7× 3.3k 0.8× 2.7k 1.1× 780 0.5× 1.4k 1.1× 181 6.7k
Mårten Fernö Sweden 52 4.1k 0.9× 4.9k 1.1× 4.0k 1.6× 1.3k 0.8× 1.9k 1.5× 232 10.0k
Serban Dan Costa Germany 37 4.2k 0.9× 4.8k 1.1× 1.3k 0.5× 1.7k 1.0× 978 0.8× 103 7.6k
Lynn G. Dressler United States 27 4.8k 1.1× 5.1k 1.2× 2.7k 1.0× 1.5k 0.9× 1.2k 1.0× 51 8.6k
Martin Köbel Canada 54 2.1k 0.5× 2.5k 0.6× 3.1k 1.2× 1.6k 0.9× 1.3k 1.0× 198 10.1k
Mark Ayers United States 33 2.7k 0.6× 5.2k 1.2× 2.5k 1.0× 780 0.5× 1.9k 1.5× 56 7.8k
Jordi Rodón United States 48 2.3k 0.5× 4.1k 1.0× 5.8k 2.3× 1.2k 0.7× 2.4k 1.9× 402 10.2k

Countries citing papers authored by Cornelia Liedtke

Since Specialization
Citations

This map shows the geographic impact of Cornelia Liedtke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cornelia Liedtke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cornelia Liedtke more than expected).

Fields of papers citing papers by Cornelia Liedtke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cornelia Liedtke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cornelia Liedtke. The network helps show where Cornelia Liedtke may publish in the future.

Co-authorship network of co-authors of Cornelia Liedtke

This figure shows the co-authorship network connecting the top 25 collaborators of Cornelia Liedtke. A scholar is included among the top collaborators of Cornelia Liedtke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cornelia Liedtke. Cornelia Liedtke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liedtke, Cornelia, Chafika Mazouni, Kenneth R. Hess, et al.. (2023). Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. Journal of Clinical Oncology. 41(10). 1809–1815. 62 indexed citations
2.
Harbeck, Nadia, Raquel von Schumann, Ronald Kates, et al.. (2021). Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer. Cancers. 13(19). 4884–4884. 10 indexed citations
3.
Kolberg, Hans‐Christian, Bahriye Aktas, & Cornelia Liedtke. (2017). Clinical Utility of Neoadjuvant Endocrine Therapy for Hormone Receptor Positive Breast Cancer. Reviews on Recent Clinical Trials. 12(2). 67–72. 1 indexed citations
4.
Bräutigam, Karen, et al.. (2016). Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate.. PubMed. 36(6). 2759–66. 9 indexed citations
5.
Radosa, Julia Caroline, Anne Eaton, Michelle Stempel, et al.. (2016). Evaluation of Local and Distant Recurrence Patterns in Patients with Triple-Negative Breast Cancer According to Age. Annals of Surgical Oncology. 24(3). 698–704. 37 indexed citations
6.
Liedtke, Cornelia & Marc Thill. (2016). AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2016. Breast Care. 11(3). 204–214. 121 indexed citations
7.
Schmidt, G, Christoph Gerlinger, Elmar Stickeler, et al.. (2016). Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer. Journal of Cancer Research and Clinical Oncology. 142(6). 1369–1376. 12 indexed citations
8.
Schwentner, Lukas, G Helms, Valentina Nekljudova, et al.. (2016). Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy – Results from the multi-center SENTINA trial. The Breast. 31. 202–207. 49 indexed citations
9.
Liedtke, Cornelia & Hans‐Christian Kolberg. (2015). Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer. Visceral Medicine. 31(6). 424–432. 2 indexed citations
10.
Bernemann, Christof, Christian Rückert, Georg Hempel, et al.. (2014). Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling. Molecular Cancer. 13(1). 174–174. 48 indexed citations
11.
Liedtke, Cornelia & Achim Rody. (2014). New treatment strategies for patients with triple-negative breast cancer. Current Opinion in Obstetrics & Gynecology. 27(1). 77–84. 18 indexed citations
12.
Dall, Peter, Cornelia Liedtke, Brigitte Rack, Florian Schütz, & Elmar Stickeler. (2013). Breast Cancer News from ASCO 2013. Breast Care. 8(4). 307–309. 4 indexed citations
13.
Kuehn, Thorsten, Ingo Bauerfeind, Tanja Fehm, et al.. (2013). Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. The Lancet Oncology. 14(7). 609–618. 928 indexed citations breakdown →
14.
Karn, Thomas, Lajos Pusztai, Eugen Ruckhäberle, et al.. (2011). Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. European Journal of Cancer. 48(1). 12–23. 39 indexed citations
15.
Moulder, Stacy, Kai Yan, Fei Huang, et al.. (2010). Development of Candidate Genomic Markers to Select Breast Cancer Patients for Dasatinib Therapy. Molecular Cancer Therapeutics. 9(5). 1120–1127. 27 indexed citations
16.
Harbeck, Nadia, Marwa Rashad Salem, Ulrike Nitz, Oleg Gluz, & Cornelia Liedtke. (2010). Personalized treatment of early-stage breast cancer: Present concepts and future directions. Cancer Treatment Reviews. 36(8). 584–594. 41 indexed citations
17.
André, Fabrice, Bastien Job, Philippe Dessen, et al.. (2009). Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array. Clinical Cancer Research. 15(2). 441–451. 248 indexed citations
18.
Rody, Achim, Uwe Holtrich, L. Pusztai, et al.. (2009). T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Research. 11(2). R15–R15. 336 indexed citations
19.
Liedtke, Cornelia, Jens Packeisen, H Schmidt, et al.. (2006). In vitro chemosensitivity testing in invasive breast cancer: Increased sensitivity of the basal subtype is not independent of the tumor proliferation rate. Clinical Cancer Research. 12. 1 indexed citations
20.
Kersting, Christian, Nicola Tidow, H Schmidt, et al.. (2004). Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. Laboratory Investigation. 84(5). 582–587. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark Basik Breakdown of academic impact, for papers by Rodrigo Dienstmann Breakdown of academic impact, for papers by Andrew H.S. Lee Breakdown of academic impact, for papers by Pär‐Ola Bendahl Breakdown of academic impact, for papers by Mårten Fernö Breakdown of academic impact, for papers by Serban Dan Costa Breakdown of academic impact, for papers by Lynn G. Dressler Breakdown of academic impact, for papers by Martin Köbel Breakdown of academic impact, for papers by Mark Ayers Breakdown of academic impact, for papers by Jordi Rodón
Rankless by CCL
2026